QDEL

Company Overview — What Does QuidelOrtho Corp Do?

QuidelOrtho Corp (QDEL) is a small-cap company in the Healthcare sector, operating within the Pharmaceutical Products industry. The stock has a market capitalization of $1.1B, making it a notable participant in its sector. Investors researching QDEL stock will find a comprehensive, data-driven analysis below covering valuation, profitability, growth, dividends, and peer comparisons for the Pharmaceutical Products space.

QuidelOrtho Corp (QDEL) Stock Rating — Avoid (April 2026)

As of April 2026, QuidelOrtho Corp receives a Avoid rating with a composite score of 23.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.QDEL ranks #4,245 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, QuidelOrtho Corp ranks #765 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

QDEL Stock Price and 52-Week Range

QuidelOrtho Corp (QDEL) currently trades at $13.85. The stock lost $0.30 (2.1%) in the most recent trading session. The 52-week high for QDEL is $38.99, which means the stock is currently trading -64.5% from its annual peak. The 52-week low is $17.02, putting the stock -18.6% above its annual trough. Recent trading volume was 2.5M shares, reflecting moderate market activity.

Is QDEL Overvalued or Undervalued? — Valuation Analysis

QuidelOrtho Corp (QDEL) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 0.37x, compared to 1.66x for the average Healthcare stock.

At current multiples, QuidelOrtho Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

QuidelOrtho Corp Profitability — ROE, Margins, and Quality Score

QuidelOrtho Corp (QDEL) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -17.7% versus the sector average of -33.1%.

On a margin basis, QuidelOrtho Corp reports gross margins of 48.4%, compared to 71.5% for the sector. The operating margin is -30.8% (sector: -66.1%). Net profit margin stands at -37.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 9.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

QDEL Debt, Balance Sheet, and Financial Health

QuidelOrtho Corp has a debt-to-equity ratio of 131.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.50x, suggesting adequate working capital coverage. Total debt on the balance sheet is $2.70B. Cash and equivalents stand at $98M.

QDEL has a beta of 1.84, meaning it is more volatile than the broader market — a $10,000 investment in QDEL would be expected to move 83.9% more than the S&P 500 on any given day. The stability factor score for QuidelOrtho Corp is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

QuidelOrtho Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, QuidelOrtho Corp reported revenue of $2.73B and earnings per share (EPS) of $-16.69. Net income for the quarter was $-1.02B. Gross margin was 48.4%. Operating income came in at $-838M.

In FY 2025, QuidelOrtho Corp reported revenue of $2.73B and earnings per share (EPS) of $-16.69. Net income for the quarter was $-1.13B. Revenue grew -1.9% year-over-year compared to FY 2024. Operating income came in at $-919M.

In Q3 2025, QuidelOrtho Corp reported revenue of $700M and earnings per share (EPS) of $-10.78. Net income for the quarter was $-733M. Revenue grew -3.7% year-over-year compared to Q3 2024. Operating income came in at $-705M.

In Q2 2025, QuidelOrtho Corp reported revenue of $614M and earnings per share (EPS) of $-3.77. Net income for the quarter was $-255M. Revenue grew -3.6% year-over-year compared to Q2 2024. Operating income came in at $-181M.

Over the past 8 quarters, QuidelOrtho Corp has demonstrated a growth trajectory, with revenue expanding from $637M to $2.73B. Investors analyzing QDEL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

QDEL Dividend Yield and Income Analysis

QuidelOrtho Corp (QDEL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

QDEL Momentum and Technical Analysis Profile

QuidelOrtho Corp (QDEL) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 42/100 reflects moderate short selling activity.

QDEL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, QuidelOrtho Corp (QDEL) ranks #765 out of 838 stocks based on the Blank Capital composite score. This places QDEL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing QDEL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full QDEL vs S&P 500 (SPY) comparison to assess how QuidelOrtho Corp stacks up against the broader market across all factor dimensions.

QDEL Next Earnings Date

No upcoming earnings date has been announced for QuidelOrtho Corp (QDEL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy QDEL? — Investment Thesis Summary

The quantitative profile for QuidelOrtho Corp suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, QuidelOrtho Corp (QDEL) earns a Avoid rating with a composite score of 23.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on QDEL stock.

Related Resources for QDEL Investors

Explore more research and tools: QDEL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare QDEL head-to-head with peers: QDEL vs AZN, QDEL vs SLGL, QDEL vs VMD.